Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nouri-Vaskeh
 
IRCT20180802040678N4
RCTangiotensin receptor blockers (ARBs)calcium channel blockerCOVID 19 hospitalizedsome concern
41/41 inconclusive
  • inconclusive 65 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 mild to moderate meta-analysis

Lopes (BRACE CORONA)
 
NCT04364893
RCTdiscontinuation of ACEI/ARBcontinuation of ACEI/ARBCOVID-19 mild to moderatesome concern
371/369 inconclusive
    9 studies excluded by filtering options (2 RCT / 7 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).